A Low-Molecular-Weight Polyethylenimine/pDNA-VEGF Polyplex System Constructed in a One-Pot Manner for Hindlimb Ischemia Therapy

被引:2
作者
Guo, Xiaoshuang [1 ,2 ]
Yuan, Zihan [1 ,2 ]
Xu, Yang [1 ,2 ]
Zhao, Xiaotian [1 ,2 ]
Fang, Zhiwei [1 ,2 ]
Yuan, Wei-En [1 ,2 ]
机构
[1] Shanghai Jiao Tong Univ, Engn Res Ctr Cell & Therapeut Antibody, Minist Educ, Shanghai 200240, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200240, Peoples R China
基金
美国国家科学基金会;
关键词
peripheral arterial disease; gene therapy; interpenetrating network; VEGF; hindlimb ischemia therapy; PERIPHERAL ARTERIAL-DISEASE; DELIVERY; ANGIOGENESIS; VECTORS; SHRNA;
D O I
10.3390/pharmaceutics11040171
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Peripheral arterial disease (PAD) is often characterized by continued reduction in blood flow supply to limbs. Advanced therapeutic strategies like gene therapy could potentially be applied to limb ischemia therapy. However, developing a gene delivery system with low toxicity and high efficiency remains a great challenge. In this study, a one-pot construction was used to integrate vector synthesis and polyplex fabrication simultaneously in a simple and robust manner. We fabricated an interpenetrating gene delivery network through the physical interaction between low-molecular-weight polyethylenimine (PEI 1.8 kDa) and plasmid DNA (pDNA) and the chemical bonding between PEI and glutaraldehyde (GA), which was named the glutaraldehydelinked-branched PEI (GPEI) polyplex. The final GPEI polyplex system was pH-responsive and biodegradable due to the imine linkage and it could successfully deliver desired vascular endothelial growth factor (VEGF) pDNA. Compared with PEI (25 kDa)/pDNA polyplexes, GPEI polyplexes showed lower cytotoxicity and higher transfection efficiency both in vitro and in vivo. In addition, we demonstrated that GPEI polyplexes could efficiently promote the formation of new capillaries in vivo, which may provide a practicable strategy for clinical hindlimb ischemia therapy in the future.
引用
收藏
页数:14
相关论文
共 36 条
[21]   Nonviral Vectors for Gene Delivery [J].
Mintzer, Meredith A. ;
Simanek, Eric E. .
CHEMICAL REVIEWS, 2009, 109 (02) :259-302
[22]  
Niiyama Hiroshi, 2009, J Vis Exp, DOI 10.3791/1035
[23]   Cell Therapy of Peripheral Arterial Disease From Experimental Findings to Clinical Trials [J].
Raval, Zankhana ;
Losordo, Douglas W. .
CIRCULATION RESEARCH, 2013, 112 (09) :1288-1302
[24]   PATHOGENESIS OF ATHEROSCLEROSIS [J].
ROSS, R .
MECHANISMS OF AGEING AND DEVELOPMENT, 1979, 9 (5-6) :435-440
[25]  
Shalhoub J, 2009, INT ANGIOL, V28, P363
[26]   Gene therapy for peripheral arterial disease [J].
Shimamura, Munehisa ;
Nakagami, Hironori ;
Taniyama, Yoshiaki ;
Morishita, Ryuichi .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (08) :1175-1184
[27]   Current therapies and investigational drugs for peripheral arterial disease [J].
Suzuki, Jun-ichi ;
Shimamura, Munehisa ;
Suda, Hiroyuki ;
Wakayama, Kouji ;
Kumagai, Hidetoshi ;
Ikeda, Yuichi ;
Akazawa, Hiroshi ;
Isobe, Mitsuaki ;
Komuro, Issei ;
Morishita, Ryuichi .
HYPERTENSION RESEARCH, 2016, 39 (04) :183-191
[28]   Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model [J].
Taguchi, A ;
Soma, T ;
Tanaka, H ;
Kanda, T ;
Nishimura, H ;
Yoshikawa, H ;
Tsukamoto, Y ;
Iso, H ;
Fujimori, Y ;
Stern, DM ;
Naritomi, H ;
Matsuyama, T .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (03) :330-338
[29]   Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial [J].
Tateishi-Yuyama, E ;
Matsubara, H ;
Murohara, T ;
Ikeda, U ;
Shintani, S ;
Masaki, H ;
Amano, K ;
Kishimoto, Y ;
Yoshimoto, K ;
Akashi, H ;
Shimada, K ;
Iwasaka, T ;
Imaizumi, T .
LANCET, 2002, 360 (9331) :427-435
[30]   Progress and problems with the use of viral vectors for gene therapy [J].
Thomas, CE ;
Ehrhardt, A ;
Kay, MA .
NATURE REVIEWS GENETICS, 2003, 4 (05) :346-358